AL
Alma Yesodot Ltd.
KVSR | TA
Overview
Corporate Details
- ISIN(s):
- IL0011731457
- LEI:
- Country:
- Israel
- Address:
- HaBarzel 3, 6971005 Tel Aviv - Jaffa
- Website:
- https://www.almayesodot.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kvasir focuses on developing innovative medical devices and diagnostic technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 17:08 |
Regulatory News Service
Opening of Trading on April 27 2025-ALMA YESODOT B1
|
Hebrew (modern) | 118.8 KB | ||
| 2025-04-23 11:59 |
Regulatory News Service
Identifying Details of New Security-ALMA YESODOT B1
|
Hebrew (modern) | 87.5 KB | ||
| 2024-11-05 15:46 |
Regulatory News Service
Changes in the company's name and security, effective as of November 7, 2024
|
Hebrew (modern) | 108.5 KB | ||
| 2024-10-29 18:37 |
Regulatory News Service
The sector classification of the company will be changed, as of October 31, 202…
|
Hebrew (modern) | 121.3 KB | ||
| 2024-10-29 17:20 |
Regulatory News Service
Base price of 1 agora and unlimited price fluctuation
|
Hebrew (modern) | 90.8 KB | ||
| 2023-05-22 23:20 |
Report Publication Announcement
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Hebrew (modern) | 174.5 KB | ||
| 2023-05-22 23:20 |
Pre-Annual General Meeting Information
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Russian | 46.0 KB | ||
| 2023-03-23 21:00 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 22.7
|
English | 1.2 MB | ||
| 2023-03-23 21:00 |
Legal Proceedings Report
Analysis update following financial report- price target is updated to NIS 22.7
|
Russian | 71.0 KB | ||
| 2022-12-11 20:40 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 32.9…
|
English | 1.2 MB | ||
| 2022-12-11 20:40 |
Business and Financial Review
Analysis update following financial report- price target is updated to NIS 32.9…
|
Russian | 67.3 KB | ||
| 2022-08-30 20:47 |
Investor Presentation
Analysis update report ,target price is at 47.6NIS
|
English | 1.2 MB | ||
| 2022-08-30 20:47 |
Business and Financial Review
Analysis update report ,target price is at 47.6NIS
|
Russian | 63.9 KB | ||
| 2022-08-18 16:58 |
Investor Presentation
Presentation
|
English | 3.0 MB | ||
| 2022-08-18 16:58 |
Pre-Annual General Meeting Information
Presentation
|
Russian | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Alma Yesodot Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Alma Yesodot Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alma Yesodot Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea
311690
South Korea
311690
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
South Korea
063160
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America
CMND
United States of America
CMND
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America
CLSD
United States of America
CLSD
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America
CLNN
United States of America
CLNN
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America
CLYM
United States of America
CLYM
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea
058820
South Korea
058820
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America
COCP
United States of America
COCP
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America
CODX
United States of America
CODX
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Germany
CNW